Is Mirum Pharmaceuticals, Inc. (MIRM) Overvalued?
We dive into why Mirum Pharmaceuticals, Inc. (MIRM) could be considered overvalued on 2026-07-27, based on AAII’s Value Score and Grade.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases; Brelovitug, for the treatment of chronic HDV infection, which is in Phase 2 clinical trial; and MRM-3379, that is in Phase 2 clinical study for the treatment of FXS. The company has a collaboration agreement with the Shire International GmbH; License Agreement with Pfizer Inc.; Sanofi-Aventis Deutschland GmbH; Novartis Pharma AG; Lonza Ltd.; Enthorin Therapeutics, LLC and Dart Neuroscience LLC; Asset Purchase Agreement with Asklepion Pharmaceuticals, LLC; License and Manufacturing Agreement with LGM Pharma; and Asset Purchase Agreement with Travere Therapeutics, Inc. The company was incorporated in 2018 and is headquartered in Foster City, California.
Commentary & Analysis
Why Mirum Pharmaceuticals, Inc.’s (MIRM) Stock Is Down 6.25%
As of Friday, July 10, Mirum Pharmaceuticals, Inc.’s MIRM share price has dipped by 6.25%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Mirum Pharmaceuticals, Inc.’s (MIRM) Stock Is Up 5.30%
As of Friday, June 26, Mirum Pharmaceuticals, Inc.’s MIRM share price has surged by 5.30%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Mirum Pharmaceuticals, Inc.’s (MIRM) Stock Is Down 5.23%
As of Monday, May 18, Mirum Pharmaceuticals, Inc.’s MIRM share price has dipped by 5.23%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Mirum Pharmaceuticals, Inc.’s (MIRM) Stock Is Up 5.67%
As of Wednesday, May 13, Mirum Pharmaceuticals, Inc.’s MIRM share price has surged by 5.67%, which has investors questioning if this is right time to sell.Jenna Brashear
Financial Summary
| Share Statistics | MIRM | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $6,461.0 | $252.6 | 71% |
|
| Shares Out (Mil) | 58.9 | 52.3 | 52% |
|
| Institutional Ownership | 98.7% | 92.1% | 81% |
|
| Float (Mil) | 52.5 | 40.2 | 48% |
|
| Beta | 0.51 | 0.95 | 28% |
|
| Avg Daily Volume (000s) | 603 | 455 | 62% |
|
| Price Change (52-week) |
107.3% | 52.9% | 92% |
|
| Growth | MIRM | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | 25.7% | (9.9%) | 81% |
|
| EPS (5yr) | 35.1% | 16.0% | 85 |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | (21.9%) | (15.6%) | 30% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 5 | 1 | 5 | |
| Current EPS | ($0.746) | ($14.240) | ($0.188) | |
| Month Ago EPS | ($0.808) | na | ($0.088) | |
| # Rev Up | 2 | 1 | 0 | |
| # Rev Down | 0 | 0 | 1 | |
| Three Months Ago EPS | ($0.430) | ($1.629) | $0.021 | |
| Year/Year Chg | (94.4%) | 2,930% | (670.2%) | |
| Financials | MIRM | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $570 | $38 | 43% |
|
| Net Income (TTM) (Mil) | ($799) | ($43) | 2% |
|
| EPS (TTM) | ($15.161) | ($1.600) | 3% |
|
| Operating Cash Flow (TTM) (Mil) | ($171) | ($31) | 4% |
|
| Net Cash Flow (TTM) (Mil) | $114 | $5 | 79% |
|
| Long-Term Debt (Q1) (Mil) | $321 | $5 | 54% |
|
| Enterprise Value (Q1) (Mil) | $5,578 | $180 | 65% |
|
| Valuation | MIRM | Industry Median |
Percentile (All Stocks) |
|
| P/B | 26.62 | 2.56 | 97% |
|
| P/E | na | 19.0 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | MIRM | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 81.4% | 63.8% | 90% |
|
| Net Margin | (140.2%) | (67.3%) | 6% |
|
| ROA | (101.0%) | (49.8%) | 5% |
|
| ROE | (335.8%) | (55.5%) | 2% |
|
| Liabilities to Assets | 72.8% | 30.3% | 68% |
|
| F-Score | 4 | 3 | 34% |
|
Mirum Pharmaceuticals, Inc. did not pass any screens on 7/31/2026.
